Literature DB >> 7695246

Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment.

C Hock, S Golombowski, W Naser, F Müller-Spahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7695246     DOI： 10.1002/ana.410370325

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  8 in total

Review 1.  Issues for clinical drug development in neurodegenerative diseases.

Authors:  Michel Dib
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

3.  On comparing 2 correlated C indices with censored survival data.

Authors:  Xiaoxia Han; Yilong Zhang; Yongzhao Shao
Journal:  Stat Med       Date:  2017-07-31       Impact factor: 2.373

4.  Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

5.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

6.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.

Authors:  N Andreasen; E Vanmechelen; A Van de Voorde; P Davidsson; C Hesse; S Tarvonen; I Räihä; L Sourander; B Winblad; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

Review 7.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

Review 8.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.